5-(1-Hydroxy-2-isobutylamino-ethyl)-benzene-1,3-diol | 53501-09-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 5-(1-Hydroxy-2-isobutylamino-ethyl)-benzene-1,3-diol
• 英文别名: 5-[1-Hydroxy-2-(2-methylpropylamino)ethyl]benzene-1,3-diol
• CAS: 53501-09-0
• 化学式: C₁₂H₁₉NO₃
• 分子量: 225.288
• InChiKey: GJQMKALYWZYYOR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  72.7
• 氢给体数：
  4
• 氢受体数：
  4

文献信息

• NOVEL CHIRAL METAL COMPLEX AND USE THEREOF FOR ANALYZING CHIRALITY OF CHARGED COMPOUND BY 1H NMR SPECTROSCOPY
  申请人：KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY

  公开号：US20170052131A1

  公开（公告）日：2017-02-23

  Provided are novel ligand, a chiral metal complex including the same, and a use of the chiral metal complex for analyzing the chirality of a charged compound by 1 H NMR spectroscopy. The chiral metal complex of the present invention may be used as the chiral solvating agent to conveniently analyze the optical purity of charged compounds such as various amine derivatives, carboxylic acid derivatives, cyanohydrin derivatives and charged metal complexes by 1 H NMR spectroscopy.

  本发明提供了一种新型配体，包括该配体的手性金属配合物，以及利用该手性金属配合物通过1H NMR光谱分析带电化合物的手性的用途。本发明的手性金属配合物可用作手性溶剂化剂，方便地通过1H NMR光谱分析各种胺衍生物、羧酸衍生物、氰醇衍生物和带电金属配合物等带电化合物的光学纯度。
• Therapeutic applications of beta-adrenergic agonists
  申请人：The Rowett Research Institute

  公开号：EP0308157A2

  公开（公告）日：1989-03-22

  This invention relates to novel therapeutic uses of beta-­adrenergic agonists in humans and animals. The uses include increasing muscle growth and reducing fat uptake from dietary input, retarding or reversing atrophy of denervated muscle, alleviating or reversing the effects of various diseases (including cancer), modification of foetal and neonatal growth, and possible genetic modifications of the developing foetus. The preferred beta-adrenergic agonist is clenbuterol. Surprisingly, the beta-adrenergic agonist can be mixed with a beta-adrenergic antagonist to obviate or mitigate unwanted side-effects without excessively inhibiting the wanted novel effects.

  本发明涉及β-肾上腺素能激动剂在人类和动物中的新型治疗用途。 这些用途包括增加肌肉生长和减少从饮食中摄取脂肪，延缓或逆转肌肉萎缩，减轻或逆转各种疾病（包括癌症）的影响，改变胎儿和新生儿的生长，以及对发育中的胎儿进行可能的基因改造。 令人惊奇的是，β-肾上腺素能激动剂可与β-肾上腺素能拮抗剂混合使用，以避免或减轻不希望出现的副作用，同时又不会过度抑制想要达到的新效果。